Related Experiment Video
Updated: Aug 23, 2025
Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
Common NLRP3 inflammasome inhibitors and Covid-19: Divide and conquer
Gaber El-Saber Batiha1, Ali I Al-Gareeb2, Damilare Rotimi3
1Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, AlBeheira, Damanhour 22511, Egypt.
Abstract:
Severe SARS-CoV-2 infection causes systemic inflammation, cytokine storm, and hypercytokinemia due to activation of the release of pro-inflammatory cytokines that have been associated with case-fatality rate. The immune overreaction and cytokine storm in the infection caused by SARS-CoV-2 may be linked to NLRP3 inflammasome activation which has supreme importance in human innate immune response mainly against viral infections. In SARS-CoV-2 infection, NLRP3 inflammasome activation results in the stimulation and synthesis of natural killer cells (NKs), NFκB, and interferon-gamma (INF-γ), while inhibiting IL-33 expression. Various efforts have identified selective inhibitors of NLRP3 inflammasome. To achieve this, studies are exploring the screening of natural compounds and/or repurposing of clinical drugs to identify potential NLRP3 inhibitors. NLRP3 inflammasome inhibitors are expected to suppress exaggerated immune reaction and cytokine storm-induced-organ damage in SARS-CoV-2 infection. Therefore, NLRP3 inflammasome inhibitors could mitigate the immune-overreaction and hypercytokinemia in Covid-19 infection.
Insights
Severe SARS-CoV-2 infection triggers harmful immune overreactions. Inhibiting the NLRP3 inflammasome may reduce this cytokine storm and organ damage in COVID-19 patients.
Area of Science:
- Immunology
- Virology
- Molecular Biology
Background:
- Severe SARS-CoV-2 infection leads to systemic inflammation and cytokine storms, contributing to high fatality rates.
- The NLRP3 inflammasome, crucial in innate immunity against viruses, is implicated in the immune overreaction seen in SARS-CoV-2 infections.
- NLRP3 inflammasome activation in SARS-CoV-2 stimulates NK cells, NFκB, and INF-γ while suppressing IL-33.
Purpose of the Study:
- To explore the role of NLRP3 inflammasome activation in SARS-CoV-2 pathogenesis.
- To identify potential therapeutic strategies targeting NLRP3 inflammasome inhibitors for COVID-19 treatment.
Main Methods:
- Review of existing literature on SARS-CoV-2, immune response, and NLRP3 inflammasome.
- Exploration of studies screening natural compounds and repurposing drugs for NLRP3 inhibition.
Main Results:
- NLRP3 inflammasome activation is a key factor in the exaggerated immune response and cytokine storm in severe COVID-19.
- Targeting NLRP3 inflammasome activation offers a potential therapeutic avenue.
Conclusions:
- NLRP3 inflammasome inhibitors hold promise for mitigating hyperinflammation and organ damage in severe SARS-CoV-2 infections.
- Further research into NLRP3 inhibitors could lead to effective treatments for COVID-19 by controlling the immune overreaction.
